ACRO BIOMEDICAL CO., LTD. (ACBM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 900K 1.8M 2.7M Q4 '17: 1.4M Q1 '18: 2M Q2 '18: 2.2M Q3 '18: 2.4M Q4 '18: 1.4M Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 193.5K Q1 '20: 688K Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 99.5K Q2 '21: 500K Q3 '21: 0 Q4 '21: 598K Q1 '22: 298.5K Q2 '22: 0 Q3 '22: 0 Q4 '22: 360K Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

0 90K 180K 270K Q4 '17: 144.5K Q1 '18: 196.4K Q2 '18: 239.9K Q3 '18: 252.6K Q4 '18: 135.4K Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 12.1K Q1 '20: 159.4K Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 29.5K Q2 '21: 80K Q3 '21: 0 Q4 '21: 150K Q1 '22: 76.5K Q2 '22: 0 Q3 '22: 0 Q4 '22: 64K Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q4 '17 Q4 '18 Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23

Operating Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q2 '16: -17.1K Q3 '16: 80.7K Q4 '16: -7.4K Q1 '17: -22.4K Q2 '17: -11.9K Q4 '17: 80.2K Q1 '18: 98K Q2 '18: 176.2K Q3 '18: 161.1K Q4 '18: -94.2K Q1 '19: -214.8K Q2 '19: -68.1K Q3 '19: -64.5K Q4 '19: -75.4K Q1 '20: 81.6K Q2 '20: -62.8K Q3 '20: -71.5K Q4 '20: -77.7K Q1 '21: -57K Q2 '21: -793.3K Q3 '21: -3M Q4 '21: -3.9M Q1 '22: -3.9M Q2 '22: -4M Q3 '22: -4M Q4 '22: -3.9M Q1 '23: -4M Q2 '23: -3.2M Q3 '23: -1.6M Q4 '23: -17.4K Q1 '24: -10.3K Q2 '24: -9.1K Q3 '24: -9.1K Q4 '24: -9.5K Q1 '25: -8.9K Q2 '25: -13.6K Q3 '25: -115.1K Q4 '25: -16.4K Q1 '26: -60.3K Q2 '26: -17.6K Q2 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q1 '15: -29 Q2 '15: -18 Q3 '15: -2.3K Q4 '15: -13.8K Q1 '16: -6.3K Q2 '16: -17.1K Q3 '16: -6.1K Q4 '16: -7.4K Q1 '17: -22.4K Q2 '17: -11.9K Q4 '17: 80.2K Q1 '18: 69.5K Q2 '18: 116.3K Q3 '18: 153.7K Q4 '18: -75K Q1 '19: -169.8K Q2 '19: -50.8K Q3 '19: -75.2K Q4 '19: -75.9K Q1 '20: 81.1K Q2 '20: -63.7K Q3 '20: -73.1K Q4 '20: -61.8K Q1 '21: -59.5K Q2 '21: -794.7K Q3 '21: -3M Q4 '21: -3.9M Q1 '22: -3.9M Q2 '22: -4M Q3 '22: -4M Q4 '22: -3.9M Q1 '23: -4M Q2 '23: -3.2M Q3 '23: -1.6M Q4 '23: -18.2K Q1 '24: -11.3K Q2 '24: -10.1K Q3 '24: -10.2K Q4 '24: -10.7K Q1 '25: -10.3K Q2 '25: -15.6K Q3 '25: -117.8K Q4 '25: 42.5K Q1 '26: -43.8K Q2 '26: -21.4K Q3 '15 Q1 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Cost of Revenue Quarterly

0 800K 1.6M 2.4M Q4 '17: 1.3M Q1 '18: 1.8M Q2 '18: 2M Q3 '18: 2.2M Q4 '18: 1.2M Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 181.4K Q1 '20: 528.6K Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 70K Q2 '21: 420K Q3 '21: 0 Q4 '21: 448K Q1 '22: 222K Q2 '22: 0 Q3 '22: 0 Q4 '22: 296K Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q4 '17 Q4 '18 Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23

Operating Cash Flow Quarterly

-600K -400K -200K 0 200K 400K 600K Q2 '15: -2.2K Q3 '15: -1.5K Q4 '15: -11.4K Q1 '16: -8.2K Q2 '16: -5.6K Q3 '16: -9.6K Q4 '16: -142 Q1 '17: -29.5K Q2 '17: -17.6K Q3 '17: -416.2K Q4 '17: -33.3K Q1 '18: 409.4K Q2 '18: -512.4K Q4 '18: 174.3K Q1 '19: -52.3K Q2 '19: -85.2K Q3 '19: 42.9K Q4 '19: 34.9K Q1 '20: -26K Q2 '20: -71.8K Q3 '20: -64.6K Q4 '20: -37K Q1 '21: -8.4K Q2 '21: 432.8K Q3 '21: -64.5K Q4 '21: -60.5K Q1 '22: 262.1K Q2 '22: -345.8K Q3 '22: -53.3K Q4 '22: -10.6K Q1 '23: -5.6K Q2 '23: 2.2K Q3 '23: 483 Q4 '23: -12.6K Q1 '24: -13.5K Q2 '24: -6.3K Q3 '24: -6.3K Q4 '24: -10.5K Q1 '25: -22.5K Q2 '25: -94K Q3 '25: -54.4K Q4 '25: -25.4K Q1 '26: -49.8K Q2 '26: -10.5K Q3 '15 Q1 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Free Cash Flow Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 25M 50M 75M Q3 '22: 60M Q1 '23: 60M Q2 '23: 60M Q3 '23: 60M Q1 '24: 60M Q2 '24: 60M Q3 '24: 60M Q1 '25: 60M Q2 '25: 60M Q3 '25: 60M Q1 '26: 60M Q2 '26: 60M Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.27 -0.18 -0.09 0.00 0.09 0.18 0.27 Q4 '15: 0.00 Q1 '16: 0.00 Q2 '16: 0.00 Q3 '16: 0.00 Q4 '16: 0.00 Q1 '17: 0.00 Q2 '17: 0.00 Q3 '17: 0.00 Q4 '17: 0.00 Q1 '18: 0.00 Q2 '18: 0.00 Q3 '18: 0.00 Q4 '18: 0.00 Q1 '19: 0.00 Q2 '19: 0.00 Q3 '19: 0.00 Q4 '19: 0.00 Q1 '20: 0.00 Q2 '20: 0.00 Q3 '20: 0.00 Q4 '20: 0.00 Q1 '21: 0.00 Q2 '21: -0.02 Q3 '21: -0.07 Q4 '21: -0.14 Q2 '23: -0.25 Q3 '23: -0.21 Q4 '23: -0.15 Q1 '24: -0.08 Q2 '24: -0.03 Q3 '24: 0.00 Q4 '24: 0.00 Q1 '25: 0.00 Q2 '25: 0.00 Q3 '25: 0.00 Q4 '25: 0.00 Q1 '26: 0.00 Q2 '26: 0.00 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.